William Blair analyst Myles Minter has reiterated their bullish stance on DNLI stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Myles Minter has given his Buy rating due to a combination of factors that highlight Denali Therapeutics’ promising future. Despite a 30% decline in share value year-to-date, the company is on the brink of becoming a commercial entity with its Tivi product, which is set for a potential approval by April 5, 2026. The commercial team is already in place, and discussions with payers are underway to secure premium pricing compared to existing treatments like Elaprase.
Furthermore, Denali is actively expanding its clinical pipeline, with plans to advance two preclinical assets by 2025 and continue this momentum annually. The company’s unique brain shuttling TV platform distinguishes it from competitors, offering significant opportunities in both rare diseases and larger indications. With Tivi and DNL126 poised to generate over $1 billion in sales and a high likelihood of approval, Minter sees a strong value proposition in Denali’s stock.
According to TipRanks, Minter is a 5-star analyst with an average return of 29.1% and a 59.85% success rate. Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Biogen, and Arcturus Therapeutics.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $32.00 price target.